Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2012

View Archived Issues

Metformin shows promise in treating prostate cancer

Plasma thymosin alpha-1 levels may distinguish renal cell carcinoma from urothelial carcinoma

Forkhead box M1 expression predictive of survival in patients with renal cell carcinoma

Novel TRPM8 antagonists designed by Mitsubishi Tanabe Pharma

Roche synthesizes new HSL inhibitors

Inwardly rectifying potassium channel, a novel immune target in MS

Novel glucocorticoid receptor ligands patented by Chiesi

GNbAC-1, a novel humanized antibody for the treatment of MS

German researchers disclose novel tubulin polymerization inhibitors

Novel GPR119 receptor agonists prepared by Boehringer Ingelheim and Neurocrine Biosciences

Novel tyrosine-protein kinase SYK inhibitors patented by GlaxoSmithKline

DKFZ and Genetic Immunity to collaborate on development of therapeutic vaccine against HPV

FDA extends review of Rytary NDA

Arena Pharmaceuticals begins phase I trial of oral candidate for pulmonary arterial hypertension

Pfizer announces topline phase III safety results for ALO-02

Canadian launch set for skin cholesterol test

Investigational drugs chosen for major Alzheimer's prevention trial

Benitec Biopharma set to acquire Tacere Therapeutics

Iverson Genetic Diagnostics signs diagnostic commercialization agreement with Johns Hopkins

Euthymics Bioscience completes enrollment in phase IIb/IIIa TRIADE trial

Cytori Therapeutics treats first patient in cell therapy trial in heart failure

SARC receives NCI grant to support sarcoma collaboration

Lexicon initiates registration trial of telotristat etiprate

FDA approves Abraxane for NSCLC

AiCuris and Merck & Co. sign exclusive worldwide license agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...